Frontiers in Anti-Cancer Drug Discovery

Frontiers in Anti-Cancer Drug Discovery

Volume: 8

Indexed in: EBSCO, Ulrich's Periodicals Directory

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest and the most important advances in anti-cancer drug design and discovery. Eminent scientists write ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Recent Development (from 2013 to 2015) of Gold- Based Compounds as Potential Anti-Cancer Drug Candidates

Pp. 104-122 (19)

Raymond Wai-Yin Sun, Chunxia Chen, Man-Kin Tse, Chih-Chiang Chen and Albert S.-C. Chan


Cisplatin (Fig. 1) is a platinum(II) compound which contains two chlorido and two ammino ligands. In 1965 the biological activity of this compound was serendipitously discovered by Rosenberg et al. At present, this platinum(II) compound remains one of the effective chemotherapeutic agents for the treatment of various cancers in clinic [1]. The clinical success of this platinum compound has subsequently prompted the studies to identify other new metal-based therapeutic agents. As compared to organic molecules, metal-based compounds have unique physical, chemical and/ or biophysical properties. In this book chapter, we summarized the very recent progress (2013-2015) from the worldwide effort in the development of novel metal-based compounds. Some recent works on the anti-cancer studies of gold compounds including that of gold(I) and gold(III) will be discussed.


Cancer, Cytotoxicity, Drugs, Encapsulation, Gold(I), Gold(III), In vitro, Medicine, Metal Complexes, MTT Assays.


Flat D35 17/F, Block D, Wah Lok Industrial Centre Phase 2, 31-35 Shan Mei Street, Fotan, N. T., Hong Kong.